A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery

NCT00332774 Phase 3 COMPLETED

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

Details

Lead sponsor	Alcon Research
Phase	Phase 3
Status	COMPLETED
Enrolment	149
Start date	2006-02
Completion	2006-12

Conditions

• Cataract

Interventions

• Nepafenac ophthalmic solution 0.1%
• Ketorolac Tromethamine ophthalmic solution 0.4%
• Nepafenac ophthalmic suspension vehicle

Primary outcomes

• Macular thickness

Countries

United States